FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial

Nature Medicine · Published 2026-07-22 · DOI 10.1038/s41591-026-04522-3

Free full text

Authors (24)

Adam D. Cohen, Joshua Richter, Suzanne Trudel, Alexander Lesokhin, Jacob P. Laubach, Sheeba K. Thomas, Simon J. Harrison, Luciano J. Costa, Andrew Spencer, Rafael Fonseca, Peter A. Forsberg, Jesus G. Berdeja, Rayan Kaedbey, Nizar J. Bahlis, Paula Rodriguez-Otero, María-Victoria Mateos, Tulika Tyagi, Divya Samineni, Wenyu Liu, Rin Nakamura, Voleak Choeurng, Chihunt Wong, James Cooper, Amrita Krishnan

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Cohen, A., Richter, J., Trudel, S., et al. (2026). FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial. Nature Medicine. https://doi.org/10.1038/s41591-026-04522-3

Related articles